SMILE—stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial

The trial has been registered prospectively on ClinicalTrials.gov under the identifier NCT05406063, as of May 3, 2022.

Authors

Alex Alfieri (ORCID: https://orcid.org/0000-0002-0209-4114)
Marc‐Eric Halatsch (ORCID: https://orcid.org/0000-0002-6981-2280)
Daniel Habermehl (ORCID: https://orcid.org/0009-0007-7316-6422)
Hossein Hemmatazad (ORCID: https://orcid.org/0000-0003-4426-6188)
Christoph Meier (ORCID: https://orcid.org/0000-0001-6944-9648)
André Buchali
Robert Foerster (ORCID: https://orcid.org/0000-0002-7664-9207)
Daniel R. Zwahlen (ORCID: https://orcid.org/0000-0003-4359-7735)
Paul Windisch (ORCID: https://orcid.org/0000-0003-1040-4888)
Daniel M. Aebersold (ORCID: https://orcid.org/0000-0002-9493-3834)
Nidar Batifi (ORCID: https://orcid.org/0009-0009-7805-8388)
Christina Schroeder

Institutions

University of Bern (CH)
Universitätsklinikum Gießen und Marburg (DE)
University Hospital of Bern (CH)
Kantonsspital Winterthur (CH)
Medizinische Hochschule Brandenburg Theodor Fontane (DE)
Università della Svizzera italiana (CH)

Publication Details

Journal: Trials
Published: 2024-11-13
DOI: https://doi.org/10.1186/s13063-024-08608-6
Primary Topic: Management of metastatic bone disease
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Berner Fachhochschule
Swiss Cancer Research Foundation

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

SMILE—stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial

Alex Alfieri, Marc‐Eric Halatsch, Daniel Habermehl, Hossein Hemmatazad et al.

Nov 13, 2024

Trials

Management of metastatic bone disease

article

SMILE—stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial

Alex Alfieri, Marc‐Eric Halatsch, Daniel Habermehl, Hossein Hemmatazad, Christoph Meier, André Buchali, Robert Foerster, Daniel R. Zwahlen, Paul Windisch, Daniel M. Aebersold, Nidar Batifi, Christina Schroeder

November 13, 2024article en

Abstract

The trial has been registered prospectively on ClinicalTrials.gov under the identifier NCT05406063, as of May 3, 2022.

TrialsVol. 25(1)

University of Bern (CH), Universitätsklinikum Gießen und Marburg (DE), University Hospital of Bern (CH), Kantonsspital Winterthur (CH), Medizinische Hochschule Brandenburg Theodor Fontane (DE), Università della Svizzera italiana (CH)

Berner Fachhochschule, Swiss Cancer Research Foundation

Openalex Percentile: Top 62%

Management of metastatic bone disease

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

SMILE—stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial — Alex Alfieri, Marc‐Eric Halatsch, et al. · Trials (2024) | TGRS Research Map | TGRS